Syngene International Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-cc9c179ad47b512fa8578e0b.pdf

Key Takeaways


Discovery Services: The Core Problem

Mittal: "Discovery will continue to be a very core part of our overall journey, but we will redo the way we have -- I mean, traditionally it's been more an FTE business, and what we are looking at is embedding AI to make it more fee-for-service, FFS value-add business."

CDMO & the Zoetis Overhang

Mittal: "But on a more sustainable basis, I think I would definitely draw your attention that hedge losses, we have changed our hedge policy and we will start moving towards more the options rather than forward contracts. And once the current hedges get over, which will be in FY '28, the sustainable level of gross margins, we are already in mid-20s."

Bayview & Biologics: The Growth Bet

Mazumdar-Shaw: "I would go so far as to say that the capacity demand for biologic manufacturing is huge. And I think right now, the ones who are capturing that opportunity are the Koreans. We would like to be the Indian company of choice, the Indian CRDMO of choice to really basically take advantage of this demand."

Margins & Cost Optimization

Mazumdar-Shaw: "Well, let me answer that by saying that every organization has to bite the bullet and do what is right for the organization. Fortunately, we have a very deep pipeline of talent in Syngene. And we have very, very good scientific talent at that."

Strategic Shifts: FTE to FFS, AI & New Modalities

Mittal: "So while you might have a lower FTE rate or a higher FTE rate, how many FTEs you're deploying is the real science. Because if you use technology, AI automation, and reduce the number of FTEs, then customers are willing to pay you premium. And that's the change in model that we are talking about."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin guidanceMaintained at mid-20s; management wants to wait another quarter before any changeFY27
Hedge losses in H2Similar level of FX hedge losses expected as in H1, from forward contracts on one large dedicated customer contractThrough FY28
Bayview process developmentProcess development activities to commence in IndiaFY27
Bayview drug substance manufacturingManufacturing to begin at the U.S. facilityFY28
Bayview commercial suppliesDependent on regulatory approval of the customer's productBest case H2 CY28
Bayview expense capitalizationPre-operative expenses capitalized until first regulatory approvalUntil H2 CY28 (best case)
Zoetis facility third-party useFacility cannot manufacture for any other customerUntil next fiscal year
Sustainable gross marginsMid-20s level already achieved on a sustainable basis, once current hedges expireFY28
SG&A expensesEndeavor to sustain at current levels, with additional benefits from cost initiativesH2 FY27
Organizational restructuring resultsResults of the restructuring and integrated model to become visibleNext two quarters

Key Metrics

MetricQ2 FY27
Revenue from operations₹833 cr, +13% QoQ, -9% YoY (absence of Zoetis revenue)
Discovery Services revenue share65% of quarterly revenue
CDMO revenue share35% of quarterly revenue
Operating EBITDA₹147 cr
Operating EBITDA margin18%, +6 ppt QoQ; adjusted for FX hedge loss would be mid-20s
Foreign exchange hedge loss₹61 cr, booked during the quarter
Profit after tax (before exceptional item)₹38 cr
Exceptional charge (employee termination benefits, net of tax)₹6 cr
Reported profit after tax₹32 cr, vs loss of ₹9 cr in Q1 FY27
Capital investment (H1 FY27)~₹200 cr, directed toward Bayview, automation, infrastructure
Net cash position₹1,392 cr at quarter end
Bayview pre-operative expenses capitalized (H1 FY27)₹66 cr
CDMO business YoY decline~2-3% (per an analyst's math), Discovery decline the larger driver of YoY revenue change
Zoetis/Librela supply obligationBack-end loaded in Q4 FY27
Biologics manufacturing capacity50 KL ready capacity